Merck Animal Health announced today the FDA approved atinvicitinib tablets (NUMELVI; Merck Animal Health), making it the first and only second-generation Janus kinase (JAK) inhibitor indicated for ...

Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered ...

Treatment with fenebrutinib significantly reduced the annualized relapse rate by 51% compared with teriflunomide. Topline data were announced from a second phase 3 trial evaluating fenebrutinib, an ...

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways JAK inhibitors can treat conditions like rheumatoid arthritis, cancer, and some skin and bowel diseases.Some JAK inhibitors have been shown to ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...